COYA
Coya Therapeutics Faces Setback as COYA 302 Delivers Mixed Results in Mid-Stage Study for Frontotemporal Dementia
Coya Therapeutics, COYA 302, Frontotemporal Dementia, Alzheimer’s Disease, Neurodegenerative Diseases, Clinical Trials, Biotechnology